Planned Parenthood on DOJ and Manufacturer Seeking Stay in Mifepristone Case
For Immediate Release: April 10, 2023
WASHINGTON D.C. — Today, the Department of Justice and manufacturer Danco Laboratories sought emergency relief to block Friday’s decision in Alliance for Hippocratic Medicine et al v. U.S. Food and Drug Administration et al staying the U.S. Food and Drug Administration’s (FDA) approval of mifepristone.
Statement by Planned Parenthood Federation of America President Alexis McGill Johnson:
“The filings make it clear: the decision to upend the FDA’s approval of mifepristone cannot be allowed to stand. Mifepristone is safe and effective, and must remain on the market. The Fifth Circuit should quickly block the Texas district court’s decision. The very legitimacy of our drug approval system is at stake.”
Read Planned Parenthood’s statement on the district court decision blocking the FDA’s approval of mifepristone here.
###
Planned Parenthood is the nation’s leading provider and advocate of high-quality, affordable sexual and reproductive health care for all people, as well as the nation’s largest provider of sex education. With more than 600 health centers across the country, Planned Parenthood organizations serve all patients with care and compassion, with respect, and without judgment, striving to create equitable access to health care. Through health centers, programs in schools and communities, and online resources, Planned Parenthood is a trusted source of reliable education and information that allows people to make informed health decisions. We do all this because we care passionately about helping people lead healthier lives. Planned Parenthood Federation of America (PPFA) is a 501(c)(3) charitable organization that supports the independently incorporated Planned Parenthood affiliates operating health centers across the U.S.